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Drug doses, blood levels of drug metabolites and myelotoxicity
during 6-mercaptopurine/methotrexate (MTX) maintenance
therapy were registered for 59 adolescents (X10 years) and
176 non-adolescents (o10 years) with B-cell precursor acute
lymphoblastic leukemia (ALL) and a white blood cell count
(WBC) o50109/l at diagnosis. Event-free survival was lower
for adolescents than non-adolescents (pEFS12y:0.71 vs 0.83,
P¼0.04). For adolescents staying in remission, the mean WBC
during maintenance therapy (mWBC) was related to age
(rS¼0.36, P¼ 0.02), which became nonsignificant for those
who relapsed (rS¼ 0.05, P¼0.9). The best-fit multivariate Cox
regression model to predict risk of relapse included mWBC
and thiopurine methyltransferase activity, which methylates
mercaptopurine and reduces the intracellular availability of
cytotoxic 6-thioguanine nucleotides (coefficient: 0.11, P¼0.02).
The correlation of mWBC to the risk of relapse was more
pronounced for adolescents (coefficient¼0.65, P¼ 0.003) than
for non-adolescents (coefficient¼0.42, P¼ 0.04). Adolescents
had higher mean neutrophil counts (P¼0.002) than non-
adolescents, but received nonsignificantly lower mercaptopurine
and MTX doses during maintenance therapy. Red blood cell
MTX levels were significantly related to the dose of MTX among
adolescents who stayed in remission (rS¼0.38, P¼0.02), which
was not the case for those who developed a relapse (rS¼0.15,
P¼0.60). Thus, compliance to maintenance therapy may
influence the risk of relapse for adolescents with ALL.
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Introduction
A majority of the collaborative groups report that children above
10.0 years of age with acute lymphoblastic leukemia (ALL) have
a worse prognosis than younger patients.1–4 This may in part
reflect that the older children more often have T-cell leukemia,5
and that their leukemic clones more commonly harbor higher
risk translocation such as t(9;22)(q34;q11) or those involving the
MLL gene, and less frequently the prognostic favorable ETV6/
RUNX1-translocations and high-hyperdiploid clones that are
common in younger children.6,7 Other, although less well
explored, risk factors for relapse among adolescents could
involve compliance to the treatment protocol, puberty-related
changes in drug disposition, and changes in the bone marrow
microenvironment.
To examine to which extent the actual compliance to the
protocol recommendations for myelosuppression influences the
risk of relapse, we retrospectively analyzed methotrexate
(MTX)/6-mercaptopurine (6MP) maintenance therapy data from
59 adolescents and 176 non-adolescents, who participated in
the Nordic Society of Pediatric Hematology and Oncology
(NOPHO) ALL92 maintenance therapy study.8 As part of that
study, we registered all data on blood counts as well as on MTX
and 6MP doses (approximately 30.000 data sets in total), and we
repeatedly analyzed the erythrocyte levels of the cytotoxic
metabolites of 6MP (that is, 6-thioguanine nucleotides, E-6TGN)
and of MTX (that is, MTX polyglutamates, E-MTX) during
therapy. The data indicate that failure to achieve the protocol
target for myelosuppression during MTX/6MP maintenance
therapy significantly increases the risk of relapse, and more so
for adolescents than for the younger patients.
Patients and methods
Patients
The NOPHO ALL92 protocol for children 1.0–14.9 years of age
with non-B-cell childhood ALL was opened in Denmark,
Finland, Iceland, Norway and Sweden on 1 January 1992.1,8
The risk group assignment was based on age and white blood
cell count (WBC) at diagnosis (standard risk: age 2.0–9.9 years
and WBC o10.0 109/l; intermediate risk (IR): age 1.0–1.9 or
X10.0 years and/or WBC 10–49.9 109/l; higher risk (that is,
high risk or very high risk): WBC X50.0 109/l) and the
presence of one or more of the following higher risk features:
T-lineage ALL, the presence of central nervous system or testicular
leukemia, translocations t(9;22)(q34;q11) or t(4;11)(q21;q23),
lymphomatous leukemia or mediastinal lymphoma, and a poor
treatment response (X25% leukemic blasts in the bone marrow
at day 15 or X5% day 29).1 In the NOPHO ALL92 protocol,
patients who had higher risk features were assigned to the very
high-risk treatment arm, if they were at least 5 years of age at
diagnosis (because of the use of cranial irradiation in that
protocol arm) and in addition had (i) T-cell disease is association
with other higher risk features, (ii) central nervous system
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leukemia, (iii) lymphomatous leukemia and/or (iv) higher risk
ALL at diagnosis andX25% leukemic blasts in the bone marrow
at day 15 or X5% day 29.9 All the remaining patients with
higher risk features were assigned to the high-risk treatment arm.
Patients with very high-risk ALL were not eligible for the
randomized NOPHO ALL92 MTX/6MP maintenance therapy
study.8 Of the 538 patients that entered the ALL92 maintenance
therapy study, 62 were above 10.0 years of age at diagnosis, and
are in this report classified as adolescents (Table 1). Of these 62
patients, only three had high-risk ALL (including one T-ALL). Of
these three high-risk ALL patients, one developed a second
malignant neoplasm, whereas the other two patients are in first
remission. As the remaining 59 patients all had IR–ALL (because
of their age at diagnosis), we only included adolescent (N¼ 59)
and non-adolescent children (N¼ 176) with IR–ALL in this
study. None of the 235 patients had Down’s syndrome. The 235
study patients were all included in the previous publication of
the NOPHO ALL92 trial, but have not previously been analyzed
separately.8
Cytogenetics
Only G-band karyotyping was mandatory in the NOPHO ALL92
protocol. However, many leukemic samples were examined by
fluorescent in situ hybridization, reverse transcriptase PCR,
comparative genomic hybridization, spectral karyotyping and/or
DNA-index by flow cytometry.10 All cytogenetic results are
scrutinized annually by the NOPHO cytogenetic working group
and described according to International System for Human
Cytogenetic Nomenclature (ISCN) 1995.11
Therapy
IR–ALL induction and consolidation therapy have previously
been described in detail.1 During induction therapy, all patients
received Prednisolone (60 mg/m2/day on days 1–36, then
tapered), weekly Vincristine (2.0 mg/m2 six times, maximum
2.0 mg), Doxorubicin (40 mg/m2 three times), Erwinia asparaginase
(30 000 IU/m2 daily on days 37–46), and intrathecal MTX on
four occasions. Subsequently, patients received two doses of
Cyclophosphamide (1000 mg/m2 two times, 4 weeks apart) with
low-dose Cytarabine (75 mg/m2 daily for two 4-day periods after
each Cyclophosphamide dose) and oral 6MP. This was followed
by oral 6MP (25 mg/m2/day) with four courses of high-dose MTX
at 2 weeks intervals. Delayed intensification consisted of
dexamethasone (10 mg/m2/day for 3 weeks, then tapered),
weekly Vincristine (2.0 mg/m2 four times), weekly Daunorubicin
(30 mg/m2/day four times) and Erwinia asparaginase (30000 IU/m2
four times) followed by Cyclophosphamide 1000 mg/m2,
low-dose Cytarabine and 6-Thioguanine. Maintenance therapy
with starting 6MP doses of 75 mg/m2/day and MTX doses of
20 mg/m2/week was initiated at treatment week 32 and
continued until 2 years from diagnosis. During the first year of
maintenance therapy, the patients received alternate pulses
of either (i) Vincristine (2.0 mg/m2 once) and Prednisolone
(60 mg/m2/day for 1 week) or (ii) high-dose MTX at 4 week
intervals until five courses of high-dose MTX had been given.
The high-dose MTX courses were given as 5 g/m2 24-h infusions
with intrathecal MTX (age-adjusted doses) and Leucovorin
rescue from hour 36 and continued at 6-h intervals until
p-MTX was o200 nM.12
Maintenance therapy randomization in NOPHO ALL92
In total, 538 patients were randomized to two different dose-
adjustment strategies of whom 235 patients had IR–ALL.8 This
includes 497% of all eligible patients during the study period.
In the control group, the dosing of oral 6MP and MTX was
targeted to a WBC of 1.5–3.5 109/l, and the doses were
recommended to be reduced to 50% at a WBC o1.5 109/l
and interrupted at a WBCo1.0 109/l and/or a thrombocyte
count o100 109/l. Therapy was reinitiated, when blood
counts were rising and WBC X1.5 109/l. Blood counts were
measured at an average interval of 1–2 weeks. If the WBC was
43.5 109/l, the protocol recommended upward dose adjust-
ments of MTX and/or 6MP, until the WBC was within the target
range. In the pharmacology group, the doses of oral 6MP and
oral MTX were adjusted according to WBC and thrombocyte
counts similar to the control group. In addition and unless the
WBC was o1.5 109/l, the doses of 6MP and/or MTX were to
be increased in steps of 20%, if E-6TGNnMTX was o1350
(nmol/mmol Hb)2 and the treating physician regarded such
upward dose adjustments to be tolerable. At least once a month,
blood samples were to be sent for E-6TGN/MTX analyses at the
Laboratory for Pediatric Oncology (Bonkolab), Rigshospitalet,
Copenhagen.13,14
Thiopurine methyltransferase activity
Interindividual variations in response to thiopurine therapy
are influenced by genetically determined polymorphisms
in the activity of the enzyme thiopurine methyltransferase
(TPMT)15,16 that methylates 6MP and some of its metabolites
and thus competes with the formation of 6TGN. In this
study, TPMT activity measurements were available for 52
adolescents (88%) and 155 non-adolescents (88%), and it was
measured 1–5 times during maintenance therapy, as described
earlier.17 For patients with more than one TPMT activity
measurement, an arithmetic mean TPMT activity was calcu-
lated. All TPMT phenotype assays were performed at least 8
weeks after the most recent blood transfusion. The TPMT activity
was not revealed to the physicians, while the patients were on
therapy.
Table 1 Clinical and pharmacological characteristics of







WBC at diagnosis (median) 17 5
t(12;21), HeH/other/N-M 11/39/29/97 2/12/15/30
Average dose 6MP (median) 57.2 52.1
Average dose MTX (median) 14.2 13.9
TPMT activity (median) 18.5 17.6
mWBC (median; 50% range) 3.1 3.3
mANC (median; 50% range) 1.9 2.2
mE-6TGN (median; 50% range) 156 191
mE-MTX (median; 50% range) 5.5 6.7
BM/CNS/other relapse 26/1/1 13/1/1
Abbreviations: 6MP, 6-Mecaptopurine; 6TGN, 6-thioguanine
nucleotides; ANC, absolute neutrophil count; BM, bone marrow
including combined relapse; CNS, isolated central nervous system
relapses; E (as prefix), erythrocyte level; HeH, high hyperdiploid (450
chromosomes); m (as prefix), time-weighted mean; MTX, Methotrex-
ate; N-M, normal or missing; TPMT, thiopurine methyltransferase;
WBC, white blood cell count at diagnosis.
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Non-parametric methods were applied to compare the distribu-
tion of parameters between subgroups and to compare the
correlation between parameters (rS¼ Spearman’s correlation
coefficient) that did not fulfill requirements for parametric
testing.18 The average dose of MTX and 6MP given to a patient
was calculated as the cumulative total prescribed dose divided
by the duration of maintenance therapy. The mean WBC,
absolute neutrophil count, and E-6TGN and E-MTX levels
during maintenance therapy was calculated as weighted means
(prefix m) using as weight the interval between the sample in
question and the next blood sample. Cox proportional hazard
backward regression analyses were performed, and the like-
lihood-ratio test was applied to test for differences in out-
come.19,20 Covariates were excluded from the models at a
significance level of 0.10. Wherein relevant, the covariates were
analyzed as time-dependent continuous parameters with re-
calculations of the weighted means of these variables every time
a patient failed using as weight the interval between the sample
in question and the next blood sample.21 Survival analyses were
carried out with a basic time scale defined by the date of
diagnosis with delayed entry of patients at the start of their
maintenance therapy. As events in the event-free survival (EFS)
analyses, we included death in remission, relapse or the
diagnosis of a second malignant neoplasm, whichever occurred
first. Patients who died in first remission or developed a second
cancer were censored at the time of these events in the analyses
of relapse risk factors. The Kaplan–Meier method was applied
for estimation of remission duration and for the generation of
survival curves.22 Subgroups were compared with the log-rank
test, stratified when needed.23 Two-sided P-values o0.05 were
regarded as being significant. Survival analyses were performed
using the SAS statistical software. SAS Institute Inc., 100 SAS
Campus Drive, Cary, NC, USA.
The protocol was approved by the ethical committee of
Copenhagen (no. V.200.2080/91) as well as by the local ethical
committees, and participants gave informed consent according
to the Helsinki Declaration.
Results
The median follow-up time for the 188 patients who remained
in first remission was 14.0 years (75% range: 12.6–15.5 years).
At the end of the study, one patient had died in first complete
remission (CR1), 43 patients had relapsed 0.9–12.0 years from
diagnosis (median: 3.0 years), and three patients had developed
a second malignant neoplasm.24 The projected 12-year EFS
(pEFS12y) and overall survival (pOS12y) of the 235 IR patients
was 80±3% and 88±2%, respectively. The 12-year EFS and
overall survival of the 59 adolescents were inferior compared
with that of the 175 younger children (pEFS12y:0.71±0.08 vs
0.83±0.03, P¼ 0.04; pOS12y:0.77±0.07 vs 0.92±0.02,
P¼ 0.003) (Figure 1).
The increased relapse risk for adolescents stayed statistically
significant when the analysis was stratified for cytogenetic sub-
groups (t(12;21)(ETV6/RUNX1)-translocation or high-hyperdiploidy
vs other aberrations vs normal or missing karyotype; P¼ 0.04).
With Cox multivariate regression analysis, we tested the effect
on risk of relapse of gender, WBC and age at diagnosis, the
average dose of MTX and 6MP, the TPMT activity, mWBC,
mE-6TGN and mE-MTX. Only the mWBC during maintenance
therapy and the TPMT activity (B (coefficient)¼ 0.11, P¼ 0.02)
were significantly and independently associated with the risk of
relapse. The effect of mWBC on the risk of relapse was more
pronounced for adolescents (B¼ 0.65, P¼ 0.003) than for the
patients below 10.0 years of age (B¼ 0.42, P¼ 0.04), and
homogeneity analysis have shown these coefficients for mWBC
differed significantly between adolescents and non-adolescents
(P¼ 0.01). Among the patients below 10.0 years of age, the
effect of mWBC on the risk of relapse did not differ significantly
when the 50 patients who had a high-hyperdiploid karytotype or
a t(12;21)(ETV6/RUNX1)-translocation were compared with the
remaining 126 patients.
The 27 adolescents randomized to pharmacological dose
adjustments did not differ significantly in their risk of relapse from
the 32 adolescents in the control group (28 vs 25%, P¼ 0.89).
For non-adolescents who stayed in remission, the mWBC
during maintenance therapy was negatively related to the age of
the patient (r¼0.08, P¼ 0.10), whereas a positive correlation
was observed for the adolescents (r¼ 0.36, P¼ 0.02) (Figure 2).
This positive correlation between mWBC and age disappeared
for adolescents who developed a relapse (r¼ 0.04, P¼ 0.9).
Overall, the median mWBC of the 59 adolescents was
3.3 109/l. The 29 adolescents with mWBC o3.3 109/l did
not differ significantly from those with higher mWBC with
respect to sex, age or WBC at diagnosis, or their average dose of
Figure 1 Probability of event-free survival (pEFS) for non-adolescents
(1.0–9.9 years, upper curve, N¼ 176) and adolescents (10.0–14.9
years, lower curve, N¼59). pEFS at 12 years: 0.83±0.03 vs
0.71±0.08, P¼0.04.
Figure 2 Scatterplot of the weighted mean WBC count during MTX/
6MP maintenance therapy in relation to age of diagnosis for
adolescents (10.0–14.9 years). A regression line is drawn for those
who did not develop a relapse (closed dots, r¼0.36, P¼ 0.02). Open
dots: patients with a relapse.
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6MP and MTX during maintenance therapy. In contrast, adoles-
cents and non-adolescents differed on several of the MTX/6MP
dose-adjustment parameters (Table 1). Thus, adolescents had
higher weighted mean WBC and absolute neutrophil count levels
during maintenance therapy (median mWBC: 3.3 vs 3.1 109/l,
P¼ 0.29; median mANC: 2.2 vs 1.9 109/l, P¼ 0.002) and they
received on average moderately lower 6MP and MTX doses
(median m6MP: 52.1 vs 57.2 mg/m2, P¼ 0.33; median mMTX:
13.9 vs 14.2 mg/m2, P¼ 0.33). In spite hereof, they had higher
weighted mean E-6TGN and E-MTX levels (median mE-6TGN: 191
vs 156 nmol/mmol Hb, P¼ 0.01; median mE-MTX: 6.7 vs
5.5 109/l, Po0.001). As the E-MTX level is significantly related
to the dose of MTX,25 we examined the correlation between the
average dose of MTX and mE-MTX. Among the 40 adolescents
who stayed in remission these two parameters were significantly
correlated (rS¼ 0.38, P¼ 0.02), whereas that was not the case for
the 15 patients who developed a relapse (rS¼ 0.15, P¼ 0.60). The
Ponte di Legno group recently suggested a WBC target for MTX/
6MP dose adjustments of 3.0 109/l.26 The adolescents and non-
adolescents in this study who had a mWBC o3.0 109/l did not
differ significantly in their EFS (0.91±0.04 vs 0.86±0.06,
P¼ 0.57), whereas for patients with a mWBC X3.0 109/l
adolescents did significantly worse than non-adolescents
(0.63±0.08 vs 0.82±0.04, P¼ 0.009).
Discussion
The present data confirm the increased relapse rate for adolescents
with ALL observed by most collaborative groups.1–3 However, in
this study adolescents with T-ALL, higher risk translocations, and/or
WBC X50 109 l at diagnosis were excluded, and the pharma-
cological data and the significant association between the degree
of myelosuppression and the risk of relapse among adolescents
indicate that other factors than just leukemia biology has a role for
the increased risk of treatment failure.
First, although nearly all collaborative ALL protocols recom-
mend the doses of MTX and 6MP during maintenance therapy to
be adjusted to a target WBC level,26 few studies have actually
examined to which extent this is achieved.8,27–33 In general, the
published studies support that low WBC levels during 6MP/MTX
maintenance therapy is linked to a reduced risk of relapse.
Furthermore, lack of physician compliance to dose titration has
been associated with an increased risk of treatment failure.31,34–36
This study emphasizes the association between the degree of
myelosuppression and the chance of cure, and indicates that this
is especially pronounced for adolescents. Furthermore, the lack
of correlation between the age and mWBC for the patients that
relapsed could indicate that the risk of relapse is related to the
absolute mWBC levels rather than to the relative degree of
myelosuppression with respect to the patients normal WBC
levels.37,38 This is important, because it indicates that although
the normal mWBC may rise with age, the target for myelosup-
pression should be the same across age groups. In this respect it
is noteworthy that adolescents with high WBC levels during
maintenance therapy did not receive significantly higher 6MP or
MTX doses than those with WBC within the target range, and
that adolescents overall received lower doses than non-
adolescents, although they in general had higher WBC levels.
The reasons for this lack of physician compliance are unclear
and calls for further exploration. However, one possible reason
could be a higher incidence of toxicity among adolescents
during maintenance therapy or earlier phases of treatment,
which could reduce the physicians willingness to treatment
intensification.39
Second, poor patient compliance to the prescribed oral doses
of 6MP/MTX has been indicated as a risk factor for relapse.40–42
Social, psychological and medical disorders may influence to
which extent adolescents take their prescribed therapy,43
and the problem is not trivial. Both electronic monitoring40
and drug metabolite measurements44 have indicated that
10–20% of childhood ALL patients intermittently fail to take
their oral medication, with a few percent being consistently
non-compliant, a problem that seems more frequent among
adolescents.45 During adolescence, parents may hand over
responsibility for the oral medication to their child, but there is
rarely available information on whether the patient or the
parents were responsible for remembering and administering the
oral medication. It is uncertain to which extent inferior patient
compliance to the prescribed MTX/6MP doses influenced the
inferior cure rate among adolescents in this study. However,
the poor correlation between the prescribed MTX doses and the
measured E-MTX levels among the adolescents who developed
a relapse could indicate poor treatment compliance for such
patients. Still, it cannot be excluded that adverse pharmacoki-
netic drug disposition rather than patient compliance deter-
mined both the increased risk of relapse and the lack of
correlation between E-MTX and the dose of MTX.
Third, young children in general have a more rapid drug
clearance than both infants and adolescents.46 This age-related
variation in drug disposition differs among the antileukemic
agents. However, based on plasma and red blood cell drug level
measurements, neither this nor previous studies indicate that the
inferior outcome of adolescents with ALL reflects adverse
bioavailability or pharmacokinetics of MTX and 6MP.47,48
However, food habits may change during the transition phase
from childhood to adolescence, and co-administration of food
with oral 6MP/MTX may influence the bioavalability and/or
pharmacokinetics of these agents.49–52 However, the higher E-
MTX and E-6TGN levels for the adolescents than for non-
adolescents who stayed in remission does not support that age-
related adverse pharmacokinetics for MTX and 6MP is a significant
reason for the increased relapse rate among adolescents.
Finally, age-related changes in sex hormone levels could have
influenced both the WBC levels during maintenance therapy
and leukemic stem cell survival. Recent studies have shown that
the efficacy of sex hormones (not least androgens) on bone
marrow failure syndromes probably is mediated by increased
telomerase activity.53 Thus, the increased levels of androgens
and estrogens during puberty could have stimulated both the
normal bone marrow activity (as indicated by the significant
positive correlation between mWBC during maintenance
therapy and the age of the patient) and the survival of malignant
stem cells. Future studies should explore whether the Tanner
stage (and/or bone age) at the time of diagnosis of ALL or at the
start of MTX/6MP maintenance therapy is related to the risk of
relapse for adolescents.
Although the number of adolescents included in this study is
limited, and the pharmacological and biological mechanism(s)
behind the association between WBC levels and risk of relapse
need further exploration, the data indicate that an increased
relapse rate for adolescents may in part reflect inferior willingness
and/or efforts of the patient, the family and/or the treating
physician to increase the intensity of maintenance therapy.
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